NASDAQ:NKTR - Nektar Therapeutics Stock Price, Forecast & News

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.17. The biopharmaceutical company earned $29.22 million during the quarter, compared to the consensus estimate of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.56) EPS. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Nektar Therapeutics.

14 Wall Street analysts have issued 1-year target prices for Nektar Therapeutics' shares. Their forecasts range from $16.00 to $43.00. On average, they anticipate Nektar Therapeutics' stock price to reach $30.46 in the next year. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

Media headlines about NKTR stock have trended very negative on Friday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of -3.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Nektar Therapeutics.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Hawkins (HWKN), Incyte (INCY), Netflix (NFLX), Gilead Sciences (GILD), Intel (INTC), Puma Biotechnology (PBYI) and AT&T (T).

Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.11%), DNB Asset Management AS (0.03%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.02%), Private Asset Management Inc. (0.01%) and FNY Investment Advisers LLC (0.01%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P. and State of Alaska Department of Revenue. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, DNB Asset Management AS, Private Asset Management Inc., Nisa Investment Advisors LLC and FNY Investment Advisers LLC. View Insider Buying and Selling for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $22.75.

Nektar Therapeutics has a market capitalization of $4.00 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.

The official website for Nektar Therapeutics is http://www.nektar.com/.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]